Chloroform → (R)-8-cyclopentyl-7-ethyl-5-methyl-2-(2-(pyrrolidin-1-yl)-1H-imidazol-1-yl)-7,8-dihydropteridin-6(5H)-one
反応式
Br[C:2]1[N:3]([C:7]2[N:16]=[CH:15][C:14]3[N:13]([CH3:17])[C:12](=[O:18])[C@@H:11]([CH2:19][CH3:20])[N:10]([CH:21]4[CH2:25][CH2:24][CH2:23][CH2:22]4)[C:9]=3[N:8]=2)[CH:4]=[CH:5][N:6]=1.[NH:26]1[CH2:30][CH2:29][CH2:28][CH2:27]1.C(Cl)(Cl)Cl.C1C=CC(P(C2C(C3C(P(C4C=CC=CC=4)C4C=CC=CC=4)=CC=C4C=3C=CC=C4)=C3C(C=CC=C3)=CC=2)C2C=CC=CC=2)=CC=1.C([O-])([O-])=O.[K+].[K+]>CC(O)(C)C.CCOC(C)=O.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[CH:21]1([N:10]2[C:9]3[N:8]=[C:7]([N:3]4[CH:4]=[CH:5][N:6]=[C:2]4[N:26]4[CH2:30][CH2:29][CH2:28][CH2:27]4)[N:16]=[CH:15][C:14]=3[N:13]([CH3:17])[C:12](=[O:18])[C@H:11]2[CH2:19][CH3:20])[CH2:25][CH2:24][CH2:23][CH2:22]1参加物
9
反応物 5
生成物 1
試薬・触媒・溶媒 3
反応条件
- 温度
- 130 °C
実験手順
(R)-2-(2-bromo-1H-imidazol-1-yl)-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Example 65, 150 mg, 0.37 mmol), pyrrolidine (52 mg, 0.74 mmol), Pd2dba3.CHCl3 (76 mg, 0.074 mmol), BINAP (69 mg, 0.11 mmol) and K2CO3 (153 mg, 1.11 mmol) were dissolved in 1 mL of degassed t-BuOH and the resulting solution was heated at 130° C. for 18 h. The reaction mixture was diluted with EtOAc and washed with brine. The organic extracts were dried with Na2SO4, filtered and evaporated, and the residue was purified by preparative HPLC to give the title compound (56 mg). LCMS: 396.2 m/z (M+H)+; ret. Time: 2.76 min (Analytical Method A).
後処理
- washwashed with brine
- dry with materialThe organic extracts were dried with Na2SO4
- filtrationfiltered
- customevaporated
- customthe residue was purified by preparative HPLC
出典と根拠
- ORDレコード
- ord-b4594beaad694721a1b74d411a3f9d6f
- 出典データセット
- uspto-grants-2013_09
- 特許番号
- US08541418B2
反応ノート
読み込み中…